Singapore, July 28 -- The Health Sciences Authority received information related to the study titled 'A Phase Ib, Open-Label, Multicenter Study of EBC-129 Combined With Osimertinib in Patients With Advanced EGFR-Mutated, Osimertinib-Resistant Non–Small Cell Lung Cancer (NSCLC)'. The following are the other relevant details related to the trial:
Therapeutic Area: Oncology (including Haematology-Oncology)
Trial Centre(s):
National Cancer Centre
Trial Status: NA
Principal Investigator(s):
Dr Tan Wan Ling
Published by HT Digital Content Services with permission from Health Daily Digest....